TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma cytologically or histologically proved or diagnosed according the criteria of the American Association for the Study of Liver Diseases(AASLD 2005)~* Three nodules maximum (unilobar disease without limitation in the number of nodules; 3 maximum nodules if bilobar disease \[satellite nodules \<1cm not included in the total sum\])~* Child-Pugh score A or B7~* ECOG Performance Status \< 2~* Platelet count \> 50,000/µl and absolute neutrophil count (ANC) \>1,000/µl~* Serum creatinine \< 150 µmol/l~* Resting ejection fraction \> 50% (echocardiography or isotopic method)~* Age \> 18 years~* Signed written informed consent~Exclusion Criteria:~* Patients eligible for surgical resection or hepatic transplantation or radiofrequency ablation~* Extrahepatic metastases~* Known gastrointestinal bleeding up to 30 days before study entry~* Patients with anticoagulant treatment~* Evidence of portal vein thrombosis~* Pregnancy~* Clinically serious infection~* Known hypersensitivity to anthracyclines~* Known hypersensitivity to contrast medium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idarubicin (Type: EXPERIMENTAL): Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of 18 to 38 kilogram/square meter (kg/m\^2) and weight \>= 40 kg at screening~* Documented physician-diagnosed asthma~* On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication~* Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted~* Evidence of uncontrolled asthma~* Use of contraceptive measures~Exclusion Criteria:~* Diagnosis of mimics of asthma~* Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator~* Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A~* Recent history of smoking~* History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results~* Asthma exacerbation within 4 weeks prior to screening~* Intubation for respiratory failure due to asthma within 12 months prior to screening~* Comorbid conditions that may interfere with evaluation of investigational medicinal product~* Known sensitivity to any of the active substances or their excipients to be administered during dosing~* Positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MSTT1041A 210 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
- MSTT1041A 490 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
- MSTT1041A 70 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating a Urinary Catheter With Different Activation Times for the Wetting Solution, in Healthy Male Volunteers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Healthy volunteer~* Male aged 18 years or over~Exclusion Criteria:~* Known or suspected, current impairment of and/or decreased urethral sensibility~* History of urethral morbidity~* History of urinary tract infection within three months, or ongoing symptomatic urinary tract infection~* Use of medications that may affect the urethra´s dryness (anti-cholinergic drugs or cortisone)~* Current drug, alcohol or other substance abuse~* Other significant disease or condition (e.g. benign prostate hypertrophy, other prostatic lesions), which may interfere with treatment and/or evaluation~* Allergy to antibiotics suspected poor compliance with the protocol during the complete study period

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours (Type: EXPERIMENTAL): All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours.
- LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds (Type: EXPERIMENTAL): All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of asthma~* Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol~* FEV1 greater than or equal to fifty percent of predicted~* Currently using moderate to high dose inhaled corticosteroid therapy~Exclusion Criteria:~* History of life threatening asthma~* Respiratory infection or oral candidiasis~* Asthma exacerbation~* Uncontrolled disease or clinical abnormality~* Allergies~* Taking another investigational medication or prohibited medication

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate/GW642444 (Type: EXPERIMENTAL): None
- Fluticasone propionate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participated in SP583~Exclusion Criteria:~* Failure to complete 12 week treatment with SPM 907

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation on the day prior to study enrollment~* Meet the best corrected visual acuity score requirement~* Meet the IOP requirement~* Additional inclusion criteria also apply~Exclusion Criteria:~* Known hypersensitivity or poor tolerance to bromfenac sodium or any component of the study medications or any of the procedural medications~* Use of any ocular topical, or systemic medication that could interfere with normal lacrimation, wound healing, the test agent, or the interpretation of study results, within 1 week prior to Day of Surgery~* Additional exclusion criteria also apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-303 BID (Type: EXPERIMENTAL): None
- ISV-303 QD (Type: EXPERIMENTAL): None
- Xibrom BID (Type: ACTIVE_COMPARATOR): None
- DuraSite Vehicle BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 40 years of age with a clinical diagnosis of Osteoarthritis (OA)of the knee for 6 months prior to study entry (ARA class I, II, or III).~* Positive therapeutic effect from prior NSAID therapy.~* Worsening of symptoms upon withdrawal of prior treatment.~* With the exception of OA, in otherwise good health~Exclusion Criteria:~* Weight no more than 280 pounds (male or female).~* Recent, sustained use of gastroprotective agents.~* History of arthroscopy of the affected knee within 6 months prior to study entry.~* History of acute ligamentous or meniscal injury of the study joint within the previous 2 years.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Participants that met the following criteria were eligible.~Inclusion Criteria:~* Symptomatic malignant ascites resulting from advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) that required at least 3 previous therapeutic paracenteses at a frequency of 1 to 4 paracenteses per month for management.~* Platinum resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.~* Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.~Exclusion Criteria:~* Peritoneovenous or other type of shunt that was placed for the management of ascites~* Prior treatment with a VEGF or VEGF receptor inhibitor~* Uncontrolled hypertension~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: EXPERIMENTAL): Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years of age or older~* Medicare beneficiaries~* Community dwelling~* Reside within defined geographical area (to enable home visits)~* Have a working telephone~* Have at least one of the following conditions documented in their electronic medical record: congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, diabetes, stroke, pneumonia, medical and surgical back conditions (predominantly spinal stenosis), hip fracture, peripheral vascular disease, cardiac arrhythmias, deep venous thrombosis, pulmonary embolism, peptic ulcer disease or hemorrhage~Exclusion Criteria:~* Current diagnosis of psychosis~* Cancer~* Dialysis~* History of organ transplantation~* Dementia without a live-in caregiver, or~* In hospice care~* Reside outside the defined geographical area~* Reside in a skilled nursing or assisted living facility

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ED-to-home care transition intervention (Type: EXPERIMENTAL): The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
- Usual Care (Type: EXPERIMENTAL): Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3471851 in Participants With Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months~* Have active AD according to study specific criteria~* Be willing and able to undergo skin biopsies~Exclusion Criteria:~* Have received certain topical medications for AD within 14 days prior to baseline~* Have received certain systemic medications for AD within 4 weeks prior to baseline~* Have received LY3471851 previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 10 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.
- 12 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
- 24 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* B-CLL~* Age \>18~* ECOG performance status 0-2~* Previous Rituximab containing induction treatment of the CLL in 1st or 2nd line~* Patient must be in complete remission or partial remission after an induction treatment containing rituximab~* ANC (absolute neutrophil count) \> 1,0 x 10e9 /L~* Life expectancy \> 6 months~* Patient´s written informed consent~* Patient using a reliable means of contraception for the duration of the treatment including 2 months thereafter~Exclusion Criteria:~* Active uncontrolled bacterial, viral or fungal infection~* Significantly reduced organ functions and bone marrow dysfunction not due to CLL~* creatinine clearance of below 30mL/min~* Patients with a history of other malignancies within 2 years prior to study entry~* Patients with a history of severe cardiac disease~* Other known comorbidity with the potential to dominate survival~* Transformation to aggressive B-cell malignancy~* Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the applied drugs~* Medical condition requiring prolonged (\> 1 month) use of oral corticosteroids~* Pregnant or breast feeding women~* Any coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Treatment with Rituximab 375 mg/m² every 3 months for 24 months
- Observation (Type: NO_INTERVENTION): Observation for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women, aged 18 - 65~* Patients with mild to moderate essential hypertension: On both screening and Day -1 visit, mean sitting DBP should be ≥ 95mmHg and ≤ 114mmHg, and ΔDBP on Day -14 and Day -1 should be within 7 mmHg~* Patients who gave their consent to participate in this study and signed the written informed consent form~* Patients who have understood the study, and been judged to be cooperative and able to participate in the study until the study completion date~Exclusion Criteria:~1. Women of childbearing potential who have not received the hysterectomy or men who are not willing to use birth control measures.~2. Patients whose sitting DBP is \< 95mmHg or ≥ 115mmHg. Patients with severe hypertension whose SBP is ≥200mmHg~3. Patients with secondary hypertension~4. Patients with severe renal disease, gastrointestinal disorder, hematologic disorder, liver disease, etc. that can affect the absorption, distribution, metabolism and excretion of drugs~5. Patients with symptoms of orthostatic hypotension~6. Patients with severe insulin dependent diabetes or uncontrolled diabetes~7. Patients who suffered myocardial infarction or serious coronary arterial disease over the past 6 months or patients with clinically significant congestive heart failure or valvular heart disease~8. Patients with consumption disease, autoimmune disease, or connective tissue disease~9. Patients with the history of type B hepatitis or type C hepatitis~10. Patients with HIV infection or hepatitis~11. Patients with clinically significant abnormal laboratory test findings~12. Patients on any drug treatment that might affect the blood pressure~13. Patients with allergy or contraindication to angiotensin II-receptor antagonists~14. Patients with current or suspected alcohol addiction or history of drug abuse~15. Patients whose mean weight lies out of the range of -15% \~ +35%, based on the Modified Metropolitan Life Insurance table~16. Patients who are not eligible as subjects of the study, as determined by the principal investigator or a sub-investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 3 tablets
- BR-A-657•K 20 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
- BR-A-657•K 60 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
- BR-A-657•K 180 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Dexamethasone on Postoperative Outcome in IBD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing elective open and laparoscopic small and large bowel operations for IBD, including Crohn's Disease(CD) and Ulcerative Colitis (UC).~2. ASA I-III~Exclusion Criteria:~1. Diabetes or hyperglycemia~2. Active gastric ulceration confirmed endoscopically~3. Presence of ongoing infection (such as IAS) or infective chronic diseases~4. Currently receiving systemic therapy with glucocorticoids with prednisolone \>=20mg for over 6 weeks within 30 days prior to surgery.~5. Emergent surgery~6. Acute angle glaucoma~7. Pregnancy~8. Under 18 years of age~9. Known adverse reaction to dexamethasone~10. Extensive adhesiolysis~11. Carcinogenesis of intestinal tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Dexamethasone 8mg intravenously prior to anesthesia induction
- Control (Type: PLACEBO_COMPARATOR): Normal Saline 1.6ml intravenously prior to anesthesia induction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete